Lubrizol integrates personal, home and health care divisions
The new brand - Lubrizol Life Sciences - aims to maximize client speed-to-market, providing enhanced solutions.
The Lubrizol Corporation has reorganized its personal, home and health care business lines, integrating them under a newly dedicated brand, Lubrizol Life Science.
The change reflects the company's commitment to evolve with the beauty, health, home and wellness markets, which continue to cross over and converge. The newly formed Lubrizol Life Science team seeks to enhance the value of its solutions and services to customers and end users through its collective expertise in chemistry, applications and market insights.
"Lubrizol Life Science brings together a great variety of formulation and product development experience to sit under one umbrella," says Lubrizol Advanced Materials President Rick Tolin. "Our internal capabilities are focused and aligned to help our customers quickly meet the expectations of today's consumers for products that ensure them of a healthier, more beautiful and comfortable life."
The newly aligned Lubrizol Life Science team is placing a priority on developing and testing products in partnership with customers, engineering breakthroughs and co-driving initiatives that fuel growth. Practices and processes emphasize agile innovation, enabling the organization to act at the speed of a start-up, while responding with the reach, resources and delivery of a global leader. The new brand will also emphasize the proactive innovation needed to bring market-ready solutions to customers, while capitalizing on the reliability of Lubrizol's 90 years of science and efficacy.
Tolin points out: "Our beauty, health and home customers can count on us bringing truly differentiated products to market, formulated with ingredients that are consumer-driven and backed by the reliability of Lubrizol." Tolin adds, "The Lubrizol Life Science team is poised to service customers throughout the value chain, from concept to commercialization. Once viewed by customers as a chemical and ingredient supplier, we have evolved into an essential, concept-to-commercialization solutions partner."
Lubrizol Life Science also plans to add strategic technology, capability and talent by investing to expand its portfolio, including new acquisitions that bring unique opportunities and synergies.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance